Last reviewed · How we verify
DDAVP
DDAVP (desmopressin) is a synthetic vasopressin analog that acts as an antidiuretic hormone (ADH) receptor agonist to increase water reabsorption in the kidneys and promote von Willebrand factor release from endothelial cells.
DDAVP (desmopressin) is a synthetic vasopressin analog that acts as an antidiuretic hormone (ADH) receptor agonist to increase water reabsorption in the kidneys and promote von Willebrand factor release from endothelial cells. Used for Central diabetes insipidus, Nocturnal enuresis, Von Willebrand disease.
At a glance
| Generic name | DDAVP |
|---|---|
| Also known as | vasopressin, Desmopressin, IN DDAVP, Octostim |
| Sponsor | Chang, Steve S., M.D. |
| Drug class | Vasopressin receptor agonist |
| Target | V2 vasopressin receptor (AVPR2) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology, Hematology |
| Phase | FDA-approved |
Mechanism of action
DDAVP binds to V2 vasopressin receptors on renal collecting duct cells, increasing aquaporin-2 water channel expression and promoting water reabsorption to concentrate urine and reduce polyuria. It also binds to V1 receptors on endothelial cells to stimulate release of von Willebrand factor and factor VIII, improving hemostasis in bleeding disorders. The drug is selective for V2 receptors at therapeutic doses, minimizing vasopressor effects.
Approved indications
- Central diabetes insipidus
- Nocturnal enuresis
- Von Willebrand disease
- Hemophilia A
- Polycystic kidney disease
Common side effects
- Hyponatremia
- Headache
- Nausea
- Abdominal pain
- Facial flushing
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis (NA)
- NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
- Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome (PHASE2)
- Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE (PHASE3)
- DDAVP Effect by TEG6 in Cardiac Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DDAVP CI brief — competitive landscape report
- DDAVP updates RSS · CI watch RSS
- Chang, Steve S., M.D. portfolio CI